- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:56 | Kaken agrees to $180M deal to develop Alumis' lead TYK2 inhibitor in Japan | ||
| Mo | Drug development cost pharma $2.2B per asset in 2024 as GLP-1s drive financial return: Deloitte | ||
| Mo | UPDATE: DOGE removes 91 federal site closures from website, including 3 FDA facilities | ||
| Mo | Unity's eye treatment fails to match Eylea, though analysts still see a path forward | ||
| Mo | Surrozen drops sole clinical-stage drug over weak hepatitis data, pivots to eye disease | ||
| Mo | Mira seeks to buy Skny for its preclinical obesity, smoking cessation asset | ||
| Mo | Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks | ||
| Mo | AbbVie takes Genmab to court, accusing partner of being 'willfully blind' to ADC trade secret theft | ||
| Mo | Opthea's eye disease drug defeated by Eylea in phase 3, leaving biotech to mull future | ||
| Fr | Chimerix engaged with 7 other biopharmas before choosing Jazz's $935M deal-here's why it won | ||
| Fr | Nvidia outlines new AI projects in robotic surgery, autonomous imaging | ||
| Fr | European countries, universities implement initiatives to attract US researchers amid 'brutal funding cuts' | ||
| Fr | Vaxart lays off 10% of staff after HHS unexpectedly demands halt to COVID vaccine trial | ||
| Fr | AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts | ||
| Fr | Eisai's abandoned Enhertu challenger set to live on at BlissBio | ||
| Fr | MacroGenics pulls plug on vobra duo ADC after seeing phase 2 prostate cancer data | ||
| Do | British investment firm secures $250M to help fund development of new dementia therapeutics | ||
| Do | Adaptimmune, after bringing cell therapy to market, questions viability and cuts 2 preclinical programs | ||
| Do | Insulet Type 1 diabetes study shows gains in 3 months after starting first automated insulin pump | ||
| Do | Elevation drops sole clinical-stage ADC over poor phase 1 data, lays off 70% of staff | ||
| Do | Monte Rosa's broad molecular glue degrader plan comes unstuck, but prostate cancer work continues | ||
| Do | BioNTech passes on Autolus' CD19/CD22 CAR-T amid pipeline prioritization | ||
| Do | Sanofi pays $600M upfront for Dren Bio's bispecific in latest immunology play | ||
| Mi | UK cell therapy biotech lays off 25% of staff, turns to tool development over therapeutics | ||
| Mi | Flatiron Health irons out pact to bring data capture tech to National Cancer Institute trial sites |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
